Group B Streptococcus Vaccine Safe and Immunogenic in Phase 1/2 Trials
Researchers conducted a Phase 1/2 placebo-controlled trial to study the safety and immunogenicity of GBS conjugate vaccination.
Researchers conducted a Phase 1/2 placebo-controlled trial to study the safety and immunogenicity of GBS conjugate vaccination.
Half of practices report having an office dismissal policy for families refusing vaccine.
AstraZeneca has resumed a phase 3 clinical trial investigating AZD1222, its COVID-19 vaccine candidate.
Fetal exposure to the H1N1 vaccine is not associated with an increased risk for autism spectrum disorder or autistic disorder in children.
Patients with myeloma should receive 2 doses of the trivalent or quadrivalent vaccine influenza vaccine and vaccinations should continue annually.
AZD1222 utilizes a replication-deficient chimpanzee adenovirus to deliver a SARS-CoV-2 protein to induce a protective immune response.
For patients with heart failure, influenza and pneumococcal vaccinations are associated with lower in-hospital mortality.
During the upcoming flu season, it is essential to ensure a high coverage rate of vaccination, particularly among populations who are vulnerable to COVID-19.
Researchers’ findings on the incidence rate of herpes zoster among unvaccinated age groups informs new set of recommendations.
An investigational inactivated whole-virus COVID-19 vaccine has demonstrated safety and immunogenicity, according to an interim analysis.